London, UK – October 10, 2026 – Despite significant strides, the landscape of women’s health innovation remains a testament to historical underfunding and data disparities. A prominent gathering at the Women’s Health Week Europe conference in London, held on October 7-8, 2026, illuminated both the progress made and the formidable challenges that lie ahead in achieving true health equity for women globally. While a more optimistic outlook is emerging, fueled by dedicated startups, engaged investors, and passionate advocates, experts underscored the critical need for inclusionary research practices and a more informed investor community to unlock the full potential of women’s health advancements.
The stark reality is that companies solely focused on women’s health have attracted a meager fraction of private healthcare investment, capturing less than 1% between 2020 and 2025, according to World Economic Forum (WEF) data. This financial deficit directly impedes the development of novel diagnostics, therapeutics, and digital health solutions tailored to the unique physiological and societal needs of women. However, the dialogue at Women’s Health Week Europe painted a picture of burgeoning momentum, with speakers highlighting tangible progress in securing a brighter future for women’s well-being worldwide.
The conference served as a crucial platform for dissecting the persistent barriers hindering this progress. A primary concern articulated by numerous experts is the pervasive data gap, which significantly complicates the development of new drugs and health technologies. This gap arises from historical biases in clinical trial design and data collection, often leading to a limited understanding of how treatments and innovations perform across the diverse female population. Furthermore, on the health technology front, patients frequently face the burden of out-of-pocket expenses for essential solutions, a reality that can disproportionately restrict access for women who may benefit the most.
Despite these systemic hurdles, a resounding theme throughout the conference was the immense, largely untapped potential of investing in women’s health. The WEF projects a compelling return on investment, predicting that for every dollar invested in women’s health, the global economy gains three dollars. Beyond economic benefits, experts emphasized the profound societal impact, including the reduction of health-related work absences and the improvement of family well-being on a broader scale, extending beyond individual women to encompass their entire support networks.
Recognizing these multifaceted benefits, several sessions at the conference delved into strategic pathways for advancing the women’s health segment. Discussions centered on optimizing financing models, refining clinical trial methodologies, and implementing systemic changes within the healthcare ecosystem to foster innovation and ensure equitable access.
The Evolving Funding Landscape for Women’s Health
A recurring challenge highlighted by founders and investors alike is the arduous journey of securing capital for nascent women’s health ventures. Henriette Hessen, Investment Director at Verdane, pointed to a significant contributing factor: the underrepresentation of women in critical decision-making roles within the finance sector. This demographic imbalance can inadvertently perpetuate biases and limit the understanding of the market potential for women-centric innovations.
Startups often begin by seeking early-stage funding, frequently turning to venture capitalists (VCs) for initial capital infusion as they establish their footing. However, the conference underscored that venture capital is far from the sole avenue for securing funding. Michael Lewis, Scientific Director of Innovation at the UK’s National Institute for Health and Care Research (NIHR), advocated for a more diversified approach, highlighting the merits of grant and debt funding, whether pursued individually or as blended financing packages. These alternative routes, he explained, offer greater flexibility for companies as they scale and evolve.
Historically, a notable disparity existed in the capital accessible to US-based versus European women’s health companies, with investment predominantly concentrating in the United States. This trend, however, is showing signs of change. Jemma Day, Investment Manager at the British Business Bank, reported a record influx of funding into women’s health in the UK and Europe during 2025, signaling a positive shift in investment priorities.
Despite this encouraging growth, Hessen noted subtle but important differences between the investor landscapes in Europe and the US. She observed that later-stage investors in the US are more frequently specialists within specific women’s health niches, whereas their European counterparts tend to adopt a more generalist investment strategy. This distinction can influence the type of support and strategic guidance available to companies at different stages of their growth.
Amidst this dynamic funding environment, Ravit Warsha Dor, Partner and Director at Telus Global Ventures, issued a prescient warning about the disruptive influence of the burgeoning artificial intelligence (AI) sector. She asserted that AI-native companies are increasingly outmaneuvering more established firms that are still grappling with legacy technologies, emphasizing the need for women’s health innovators to embrace and integrate cutting-edge technologies to remain competitive.
Optimizing Research: Ensuring Women Are at the Forefront
The pursuit of population-level health improvements is intrinsically linked to advancements in pharmaceutical treatments, which play a pivotal role in managing existing conditions and enhancing patient longevity and quality of life. However, a significant and persistent issue is that many widely prescribed medications have historically been tested predominantly on male subjects. This practice has resulted in a less comprehensive understanding of drug safety and efficacy in women, leading to a higher incidence of serious treatment-emergent adverse events (TEAEs) among female patients compared to their male counterparts.
Experts at the conference expressed grave concern that this problem will persist without concerted action. The alarming statistic that 72% of clinical trials currently fail to disaggregate outcomes by sex underscores the depth of this data deficit. Lale Say, Unit Head at the World Health Organization (WHO), stressed the imperative for sponsors to routinely incorporate sex-disaggregated data into their analyses. By embedding this practice into global policy, researchers can gain crucial insights into potential sex-based differences in safety risks, whether those risks are skewed towards men or women.
While commendable progress has been made in closing the sex-based gap in clinical trial participation, the representation of women from marginalized groups within research remains a critical area for improvement. Maryann Ferreux, CMO at Health Innovation Kent Surrey Sussex, emphasized the heterogeneity within the female population, stating, "Women are not one homogeneous group; there’s intersectionality in there." She underscored that factors beyond sex, such as socioeconomic demographics and ethnicity, are equally vital considerations for sponsors aiming to close the data gap comprehensively.
Alison Cave, Chief Safety Officer of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), also made a strong plea for the inclusion of data pertaining to drug safety and efficacy in pregnant and lactating individuals. Information regarding the impact of certain essential medications on both mothers and their developing children remains scarce, posing potential risks to vulnerable populations. To achieve widespread improvements in patient outcomes, experts unanimously agreed on the importance of collecting more robust data, both in the pre- and post-marketing phases, to gain a more accurate understanding of a treatment’s true impact across diverse patient groups.
Addressing Systemic Challenges to Accelerate Women’s Health Progress
As the women’s health segment endeavors to achieve further breakthroughs, it must confront a spectrum of systemic challenges that have historically impeded progress. These include dismantling pervasive misogyny within both the healthcare system and broader society, significantly bolstering financial investment in women’s health initiatives, and implementing policies that are proactively designed with women’s health needs at their core.
Overcoming these deeply entrenched hurdles, experts emphasized, requires a collective and concerted effort. It cannot be an isolated endeavor. Investors, clinicians, regulators, policymakers, and founders all bear a shared responsibility in driving this transformative change. Moreover, the scope of this undertaking must be global, recognizing that health disparities disproportionately affect women from disadvantaged backgrounds across the world.
While collaborative efforts among stakeholders can undoubtedly lead to significant advancements in women’s health, the CEO of the period tracker app, Clue, cautioned that these initiatives will ultimately fall short if there isn’t widespread access to beneficial therapeutics and health technologies for all segments of the patient population. To achieve this crucial goal, she posited that a fundamental focus on distribution strategies and their successful implementation must be integrated into the earliest stages of the development process.
In conclusion, the consensus among experts at the 2026 Women’s Health Week Europe conference was one of cautious optimism. While acknowledging the significant momentum and potential within the women’s health sector, they underscored the persistent research, data, and systemic obstacles that must be diligently addressed to realize the ultimate vision of true health equity for women globally. The path forward demands a paradigm shift towards inclusive research, informed investment, and a unified commitment to dismantling the barriers that have long hindered the full realization of women’s health potential.
About the Author
